Restless legs syndrome: a review of diagnosis and management in primary care (Q38113094)

29 August 2017

title

Restless legs syndrome: a review of diagnosis and management in primary care (English)

1 reference

29 August 2017

main subject

restless legs syndrome

1 reference

Richard K Bogan

1 reference

29 August 2017

James A Cheray

series ordinal

1 reference

29 August 2017

language of work or name

English

0 references

publication date

1 May 2013

1 reference

29 August 2017

published in

Postgraduate Medicine

1 reference

29 August 2017

volume

125

1 reference

29 August 2017

1 reference

29 August 2017

page(s)

99-111

1 reference

Restless legs syndrome prevalence and impact: REST general population study

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Restless legs syndrome and periodic leg movements in sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Restless legs syndrome: Understanding its consequences and the need for better treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Circadian rhythm of motor restlessness and sensory symptoms in the idiopathic restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Restless legs syndrome: pathophysiology, clinical presentation and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Diagnosing restless legs syndrome (RLS) in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Prevalence of restless legs syndrome in North American and Western European populations: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Restless legs syndrome symptoms in primary care: a prevalence study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Algorithms for the diagnosis and treatment of restless legs syndrome in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

The role of iron in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

CSF iron, ferritin and transferrin levels in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Neuroanatomical study of the A11 diencephalospinal pathway in the non-human primate

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Iron deficiency alters the day-night variation in monoamine levels in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Iron deficiency alters dopamine uptake and response to L-DOPA injection in Sprague-Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Animal models of restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Diurnal cycle influences peripheral and brain iron levels in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

MRI measurement of brain iron in patients with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Multiregional brain iron deficiency in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

A genetic risk factor for periodic limb movements in sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

An algorithm for the management of restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Imbalance between thyroid hormones and the dopaminergic system might be central to the pathophysiology of restless legs syndrome: a hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions ("mimics").

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Restless legs syndrome and its relationship with insomnia symptoms and daytime distress: epidemiological survey in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Epidemiology of restless legs in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Effects of restless legs syndrome (RLS) on sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Restless legs syndrome: a clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Prevalence and correlates of restless legs syndrome symptoms in the Wisconsin Sleep Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Psychological distress of patients suffering from restless legs syndrome: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Prevalence and correlates of restless legs syndrome: results from the 2005 National Sleep Foundation Poll

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Evaluating the quality of life of patients with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Depressive disorders in restless legs syndrome: epidemiology, pathophysiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

"Anxietas tibiarum". Depression and anxiety disorders in patients with restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Prospective survey on the natural course of restless legs syndrome over two years in a closed cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Restless legs syndrome and hypertension in middle-aged women

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Nocturnal blood pressure changes in patients with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Dopaminergic augmentation of restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Restless legs syndrome improved by pramipexole: a double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study--the PRELUDE study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Low-dose pramipexole in the management of restless legs syndrome. An open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Efficacy and safety of pramipexole in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Long-term open-label study of pramipexole in patients with primary restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Ropinirole improves depressive symptoms and restless legs syndrome severity in RLS patients: a multicentre, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Efficacy and safety of dopamine agonists in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Long‐term management issues in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Medication tolerance and augmentation in restless legs syndrome: the need for drug class rotation

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Double-blind evaluation of clonazepam on periodic leg movements in sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Zolpidem in restless legs syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Prevalence of restless legs syndrome and periodic limb movement disorder in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Epidemiology of restless legs symptoms in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

Restless legs syndrome as side effect of second generation antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2013.05.2636

21 January 2018

Identifiers

DOI

10.3810/PGM.2013.05.2636

1 reference

29 August 2017

1 reference